1. Home
  2. PEBK vs NKTX Comparison

PEBK vs NKTX Comparison

Compare PEBK & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peoples Bancorp of North Carolina Inc.

PEBK

Peoples Bancorp of North Carolina Inc.

HOLD

Current Price

$36.89

Market Cap

157.0M

Sector

Finance

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.40

Market Cap

132.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEBK
NKTX
Founded
1912
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.0M
132.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PEBK
NKTX
Price
$36.89
$2.40
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$13.25
AVG Volume (30 Days)
9.7K
754.6K
Earning Date
02-11-2026
11-10-2025
Dividend Yield
2.66%
N/A
EPS Growth
3.81
N/A
EPS
3.06
N/A
Revenue
$85,500,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.06
N/A
Revenue Growth
6.88
N/A
52 Week Low
$23.74
$1.31
52 Week High
$38.46
$2.74

Technical Indicators

Market Signals
Indicator
PEBK
NKTX
Relative Strength Index (RSI) 59.51 72.37
Support Level $36.05 $1.93
Resistance Level $37.60 $2.19
Average True Range (ATR) 0.79 0.12
MACD -0.10 0.03
Stochastic Oscillator 72.11 98.21

Price Performance

Historical Comparison
PEBK
NKTX

About PEBK Peoples Bancorp of North Carolina Inc.

Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: